What hepatitis C screening actually measures
Screening for hepatitis C is a blood test, but the two main tests answer different questions. An antibody test (anti-HCV) shows whether the immune system has responded to the virus at some point. It does not by itself show whether the virus is still present. A reactive antibody result therefore leads to a second step: an HCV RNA test, sometimes called a viral load or nucleic acid test, which detects the virus's genetic material in the blood.
That distinction matters for planning. Someone whose antibody test is reactive but whose RNA test is negative may have cleared an earlier infection, either spontaneously or after treatment. Someone with detectable RNA has a current infection and needs clinical assessment. A clinician interprets both results together with liver tests and the person's history; the tests are pieces of evidence, not a verdict the patient should read alone.
Screening is also different from testing because of symptoms. If you have current symptoms such as jaundice, unusual fatigue or abdominal discomfort, that calls for a clinical consultation rather than a screening package. Screening programmes are designed for people without symptoms, and a symptomatic person needs assessment, not a routine test bought in advance.
Who should ask about screening, and why it is worth asking
Hepatitis C is often silent for years, which is the main argument for screening people with risk factors rather than waiting for symptoms. Well-established risk factors include having received a blood transfusion or blood products before screening of donated blood became routine in the country concerned, past or current injecting drug use, some types of medical or dental procedures with inadequate infection control, needlestick injuries in healthcare work, and being born to a mother with hepatitis C. Sharing personal items that can carry blood, such as razors, is also discussed as a risk in some guidance.
The exact thresholds and the age-based or risk-based approach differ between countries and between guidelines. Rather than assume a rule applies in China, ask the clinician or screening provider which criteria they use and whether your history meets them. If you already know you were exposed, or a previous test was reactive, say so at the first contact; that changes the conversation from screening to confirmation and assessment.
There is a practical reason to clarify this early. A screening package built for healthy adults may not be the right route for someone with a known exposure or an abnormal liver test. The provider should tell you whether your situation fits a routine screening pathway or needs a specialist appointment, and that decision belongs to the clinical team.
How a screening visit in China can be organised
For an international patient, the realistic route is a hospital or clinic that can draw the blood, run or send out the laboratory tests, and give you results with an explanation. Larger tertiary hospitals and private international clinics are both possible settings, and the right choice depends on whether you need only a screening test or a fuller assessment. Ask directly whether the site can perform both the antibody and the RNA test, and whether the RNA result is reported with an interpretable value rather than a simple positive or negative.
Language and reporting are practical questions, not marketing points. Ask whether results and any interpretation will be provided in English, who will explain a reactive result, and how a follow-up appointment would be arranged if confirmation is needed. Do not assume a fixed turnaround; laboratory reporting depends on the test and the facility, so confirm the expected timing with the specific provider.
If you are planning a broader health review, screening can be discussed alongside it, but keep the two purposes separate. A routine checkup package is not a substitute for targeted hepatitis testing, and a reactive screening result should trigger a clinical conversation rather than a repeat of the same package. The checkup route is described on the health checkup packages page, while a reactive result or known exposure belongs with a specialist.
What a reactive result means and what happens next
A reactive antibody result is not the same as a current infection, and it is not a reason to panic before confirmation. The next step is an HCV RNA test, and the clinician will interpret it alongside liver enzyme tests and your history. If RNA is detectable, the conversation turns to assessment: how long the infection may have been present, whether there is evidence of liver inflammation or fibrosis, and which treatment options are appropriate. Modern direct-acting antiviral treatment has changed the outlook for hepatitis C substantially, but whether and when treatment applies to you is a clinical decision.
If RNA is not detectable, the clinician will explain what that means in your case, including whether any further follow-up is needed. Do not assume a negative RNA result closes the matter without a clinician's explanation, and do not start or stop any medicine based on a test result you have read alone.
One point deserves care: screening does not establish that treatment is available, suitable or funded for you in China. Availability of specific medicines, eligibility rules and cost arrangements are matters for the treating hospital and, where relevant, the relevant authorities. Ask the clinical team what they can confirm for your situation rather than relying on general statements about hepatitis C treatment.
Records and questions to bring to the first appointment
Bring what you already have rather than waiting for a complete archive. Previous hepatitis test results with dates and the laboratory's reference ranges are the most useful items, because they show whether an antibody or RNA test was done and what it found. Liver function blood tests, any imaging of the liver, and a list of current medicines and relevant history help the clinician build a picture. If you were treated for hepatitis C before, bring the treatment record and any post-treatment test results.
Prepare a short list of questions. Which test does this provider use first, and is RNA testing available on site? How will a reactive result be explained to me, and by whom? What does the clinician need to judge whether I need assessment for liver fibrosis? If treatment is considered, what would the plan involve and what would I need to arrange? These questions are more useful than a long generic checklist, and the answers tell you whether the provider fits your situation.
It also helps to be clear about what you want from the visit. Some people want only a screening result and an explanation; others want a fuller liver assessment. Saying which at the start lets the provider tell you whether one appointment is realistic or whether the pathway involves more steps, without anyone promising a schedule in advance.
Practical boundaries before you travel
Screening is a laboratory and clinical process, and several things cannot be settled from abroad. Whether a particular hospital will accept you as a patient, which tests it will order, how results will be communicated and what any treatment would involve are decisions for that hospital and its clinicians. A records-based review can help clarify the questions, but it does not establish hospital acceptance, treatment eligibility or a final plan.
Cost is another area to confirm rather than assume. Screening tests, confirmation tests, consultations and any treatment are charged by the hospital or provider, and coordination services are separate. Ask for a written statement of what a quoted fee covers before you commit, and ask whether confirmation testing or a follow-up consultation would be billed separately. Without a written quote for your situation, any figure you see elsewhere may not apply to you.
Finally, keep urgency in perspective. If you develop symptoms that worry you, seek local medical care rather than waiting for an overseas appointment. For a routine screening question, the sensible next step is a short enquiry describing your history and what you want to know, so the team can tell you which records matter and whether a specialist appointment is the right route. An initial enquiry is free and does not commit you to a proxy consultation.
Sources & scope of this guide
References and official service information relevant to this guide.
- Health checkup packages
- https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
- https://www.cdc.gov/hepatitis-c/testing/index.html
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
